


## Computational modeling reveals multiple abnormalities of myocardial noradrenergic function in Lewy body diseases

David S. Goldstein, ... , Graeme Eisenhofer, Yehonatan Sharabi

*JCI Insight*. 2019. <https://doi.org/10.1172/jci.insight.130441>.

Clinical Medicine In-Press Preview Cardiology Neuroscience

### Graphical abstract



Find the latest version:

<https://jci.me/130441/pdf>



# **Computational modeling reveals multiple abnormalities of myocardial noradrenergic function in Lewy body diseases**

David S. Goldstein, MD PhD<sup>1</sup>

Mark J. Pekker (formerly Mark J. Friedman), PhD<sup>2</sup>

Graeme Eisenhofer, PhD<sup>3</sup>

Yehonatan Sharabi, MD<sup>4</sup>

*<sup>1</sup>Autonomic Medicine Section (formerly Clinical Neurocardiology Section), Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892*

*<sup>2</sup>Mathematical Sciences, University of Alabama at Huntsville, Huntsville, AL*

*<sup>3</sup>Institute of Clinical Chemistry and Laboratory Medicine and Department of Medicine, Technische Universität Dresden, Dresden, Germany*

*<sup>4</sup>Tel Aviv University Sackler Faculty of Medicine and Chaim Sheba Medical Center, Tel HaShomer, Israel*

Corresponding Author: David S. Goldstein, MD PhD, Autonomic Medicine Section (formerly Clinical Neurocardiology Section, CNP/DIR/NINDS/NIH, 9000 Rockville Pike MSC-1620, Building 10 Room 8N260, Bethesda, MD 20892-1620 USA. Cell phone: 301-675-1110. Fax: 301-402-0180. Email: [goldsteind@ninds.nih.gov](mailto:goldsteind@ninds.nih.gov).

Short title: Cardiac SNS in Lewy Body Diseases

Counts: Abstract words: 250; Manuscript words: 3,295; Figures: 4; Tables: 4; References: 51; Supplementary Spreadsheets: 3

Key words: Catecholamine; Lewy body; Sympathetic nervous system; Norepinephrine; Dopamine

## ABSTRACT

**Background:** Lewy body diseases, a family of aging-related neurodegenerative disorders, entail loss of the catecholamine dopamine in the nigrostriatal system and equally severe deficiency of the closely related catecholamine norepinephrine in the heart. The myocardial noradrenergic lesion is associated with major non-motor symptoms and decreased survival. Numerous mechanisms determine norepinephrine stores, and which of these are altered in Lewy body diseases has not been examined in an integrated way. We used a computational modeling approach to assess comprehensively pathways of cardiac norepinephrine synthesis, storage, release, reuptake, and metabolism in Lewy body diseases. Application of a novel kinetic model identified a pattern of dysfunctional steps contributing to norepinephrine deficiency. We then tested predictions from the model in a new cohort of Parkinson disease patients.

**Methods:** Rate constants were calculated for 17 reactions determining intra-neuronal norepinephrine stores. Model predictions were tested by measuring post-mortem apical ventricular concentrations and concentration ratios of catechols in controls and patients with Parkinson disease.

**Results:** The model identified low rate constants for three types of processes in the Lewy body group—catecholamine biosynthesis via tyrosine hydroxylase and L-aromatic-amino-acid decarboxylase, vesicular storage of dopamine and norepinephrine, and neuronal norepinephrine reuptake via the cell membrane norepinephrine transporter. Post-mortem catechols and catechol ratios confirmed this triad of model-predicted functional abnormalities.

**Conclusion:** Denervation-independent impairments of neurotransmitter biosynthesis, vesicular sequestration, and norepinephrine recycling contribute to the myocardial norepinephrine deficiency attending Lewy body diseases. A proportion of cardiac sympathetic nerves are “sick but not dead,” suggesting targeted disease-modification strategies might retard clinical progression.

**Trial registration:** This study was not a clinical trial.

**Funding:** The research reported here was supported by the Division of Intramural Research,  
NINDS.

## INTRODUCTION

The movement disorder in Parkinson disease (PD) results from depletion of the catecholamine dopamine in the brain's nigrostriatal system (1). PD also entails profound deficiency of the closely related catecholamine norepinephrine (NE) in the heart (2). Other Lewy body diseases—pure autonomic failure (PAF) and dementia with Lewy bodies—also involve severely decreased myocardial NE contents (3).

The cardiac sympathoneural lesion in these diseases probably is important clinically. Thus, neuroimaging evidence of cardiac noradrenergic deficiency in PD is associated with cognitive impairment (4), exercise intolerance (5), olfactory dysfunction (6), rapid eye movement behavior disorder (7), visual hallucinations (8), falls from neurogenic orthostatic hypotension (9), fatigue (10), and shortened survival (11).

One might presume that the myocardial NE depletion in these disorders directly and solely reflects loss of sympathetic noradrenergic nerves; however, studies using immunoreactive tyrosine hydroxylase (TH) as a marker of myocardial catecholaminergic innervation have noted about a 75% average decrease in PD (12-17), whereas, as confirmed here, the extent of loss of NE is 95-99% (2, 3). The greater magnitude of neurotransmitter depletion than of loss of sympathetic noradrenergic innervation suggests the occurrence of abnormalities in residual nerves that are dysfunctional but extant. We call this the “sick but not dead” phenomenon.

There are many such potential abnormalities (Figure 1), including decreased vesicular uptake of cytoplasmic catecholamines via the type 2 vesicular monoamine transporter (VMAT); (18) increased vesicular permeability (19); decreased axonal transport of vesicles or vesicle-associated proteins (20); decreased activities of the enzymes TH (21), L-aromatic amino acid decarboxylase (LAAAD) (22), and vesicular dopamine-beta-hydroxylase (DBH) (23); increased exocytotic release of vesicular NE (24); and decreased neuronal NE recycling via the Uptake-1 process mediated by the cell membrane NE transporter (NET) (25).

Previous studies and kinetic models (26) have not provided a cohesive, comprehensive view of overall cardiac catecholaminergic functioning in Lewy body diseases. In the present

study we used a novel systems biologic approach by constructing and applying a detailed computational model that enabled a more complete picture.

A rich fund of *in vivo* neurochemical, neuroimaging, and tracer kinetic data has accumulated over many years about cardiac noradrenergic function in healthy humans (27) and in a variety of clinical disorders (28), and post-mortem studies have provided data about myocardial tissue contents of NE, dopamine, and other compounds of interest in Lewy body diseases (2, 3). We exploited this information to assess for the first time all the major known pathways of cardiac catecholamine synthesis, release, recycling, and metabolism simultaneously, with the goal of identifying the intra-neuronal functional abnormalities contributing to myocardial noradrenergic deficiency in Lewy body diseases. We hypothesized that in addition to sympathetic denervation a multiplicity of functional abnormalities in residual nerves work together to cause the dramatic loss of myocardial NE stores that characterizes Lewy body diseases.

The model we used describes rates of 17 intra-neuronal catecholamine-related reactions and amounts of 9 intra-neuronal reactants (Figure 1, Table 1). Differential equations presuming equilibrium conditions were used to calculate rate constants for each of the intra-neuronal reactions in controls and Lewy body disease patients (see Appendices).

We tested predictions from the model using new data about post-mortem concentrations and ratios of apical left ventricular catechols in cohorts of autopsy-proven PD patients and control subjects.

## RESULTS

The Lewy body disease group had drastically decreased myocardial tissue contents of NE (by 96% from controls) and dopamine (by 95%) (Table 1; individual data with descriptive statistics are in Supplementary Spreadsheet A). There were smaller proportionate decreases in amounts of other catechols. The Lewy body disease group also had severely decreased rates of cardiac spillover of NE (by 86% from control), DHPG (by 97%), DOPA (by 84%), and DOPAC (by 98%) (individual data with descriptive statistics are in Supplementary Spreadsheet B).

### Calculated rate constants in controls

Based on inputs for the model (Tables 2 and 3), in controls the calculated rate constant for TH ( $k_{TH}$ ) was 1.9% that for LAAAD (Figure 1, Table 4).  $k_{VMAT\_DA}$  was about 7 times  $k_{MAO\_DA}$ , and  $k_{VMAT\_NE}$  was about 11 times  $k_{MAO\_NE}$ . The rate constant for neuronal uptake of NE from the extracellular fluid ( $k_{U1}$ ) was about 11 times that for loss of extracellular fluid NE from the tissue ( $k_{NE\_Loss}$ ).

### Calculated rate constants in Lewy body disease patients

Compared to the control group, the Lewy body disease had lower values for  $k_{U1}$  (2% of control),  $k_{LAAAD}$  (8%),  $k_{TH}$  (30%),  $k_{NEe\_Loss}$  (19%),  $k_{MAO\_DA}$  (27%),  $k_{VMAT\_NE}$  (28%),  $k_{MAO\_NE}$  (35%), and  $k_{VMAT\_DA}$  (74%), with higher values for  $k_{DBH}$  (320%),  $k_{Leak\_DA}$  (208%),  $k_{Leak\_NE}$  (205%), and  $k_{NE\_Release}$  (141%) (Figure 1, Table 4).

Across the series of reactions from TH to LAAAD and from LAAAD to VMAT<sub>DA</sub>, the product of the percents of control was 1.9%, meaning a 98.1% decrease in synthesis and vesicular uptake of cytoplasmic dopamine.

Curves showing amounts of reactants as functions of isolated decreases in rate constants failed to generate the pattern of abnormalities of reactants observed in the Lewy body group (Figure 3). That is, no single abnormality was sufficient to reproduce the observed differences between the control and Lewy body groups.

### Testing model predictions

In new subject cohorts of PD patients and controls, myocardial NE content was decreased

by 99% in the PD group (Figure 4; individual data with descriptive statistics are in Supplementary Spreadsheet C).

Myocardial concentrations ratios of DHPG/NE in the PD group averaged 9.8 times, DOPAC/NE 11.2 times, and DOPAC/DA 14.8 times control ( $p=0.00002$ ,  $p<0.00001$ ,  $p=0.0004$ ; Figure 5 and Supplementary Spreadsheet C). Concentration ratios of DOPA/DOPAC, Cys-DOPA/DOPAC, and (DOPA+Cys-DOPA)/DOPAC in the PD group averaged 5.1, 3.5, and 5.0 times control ( $p=0.002$ ,  $p=0.0004$ ,  $p=0.002$ ). The mean value for (DOPA+Cys-DOPA) adjusted for LAAAD activity in the PD group averaged 30% that in the controls ( $p=0.004$ ; Fig. 5).

Myocardial epinephrine in the PD group averaged 14.2% that in the controls ( $p<0.0001$ ; Supplementary Spreadsheet C).

## DISCUSSION

### *“Sick but not dead”*

As reported recently (3) and confirmed here, Lewy body diseases entail profound cardiac NE depletion. The remarkably severe extent of this deficiency (99% in the present study) is greater than can be accounted for by sympathetic denervation alone (about 75% based on immunoreactive TH in left ventricular myocardial tissue) (12-17). How can there be greater loss of a neurotransmitter than of the nerves that contain the neurotransmitter? Based on the results of this study, the resolution of this apparent paradox is substantial abnormalities in the synthesis, storage, and recycling of NE in residual nerves that are dysfunctional but extant—i.e., “sick but not dead.”

### *Reasonableness of the kinetic model*

Review of the literature indicates that the comprehensive kinetic model we developed was reasonable. First, TH is well known to be the rate-limiting enzyme in catecholamine biosynthesis (29), and in the present study the calculated rate constant for TH was about 1/50<sup>th</sup> that for the next enzyme in the synthetic cascade, LAAAD. Second, vesicular uptake is the dominant mode of disposition of cytoplasmic catecholamines (30), and the model-calculated rate constants for vesicular uptake of cytoplasmic dopamine and NE each were about 12 times those for MAO acting on these catecholamines. Third, about 90% of released NE is removed by neuronal reuptake (28), and in the model the rate constant for Uptake-1 was 11.5 times the rate constant for loss of extracellular NE from the tissue. Fourth, under resting conditions most of the turnover of catecholamines occurs not by release and escape of neuronal reuptake but by leakage from the vesicles into the cytoplasm and enzymatic deamination catalyzed by MAO (30), and the calculated rate constant for NE leakage was about 5 times that of exocytotic NE release.

There was a huge range of values for the model-generated rate constants—from about 0.00020 min<sup>-1</sup> for k<sub>TH</sub> to almost 20 min<sup>-1</sup> for k<sub>U1</sub>. This span is also reasonable, as follows. The value for k<sub>TH</sub> in the model agreed well with that calculated from data published by Nagatsu et al. in their initial description of TH as the rate-limiting enzyme in catecholamine biosynthesis

(29). Regarding U1 we previously estimated a much lower rate constant— $0.55 \text{ min}^{-1}$ —based on the kinetics of the cardiac sympathetic imaging agent,  $^{18}\text{F}$ -dopamine (31). The higher rate constant in the present model could reflect the use of an assumed NE amount of 0.14 nmoles in the extracellular fluid. This was calculated indirectly from a published microdialysate NE concentration in rat myocardium (0.001 nmol/mL) (32), and microdialysate NE could have substantially underestimated NE at U1 sites, in which case  $k_{U1}$  in the model would be overestimated. Even so, the literature indicates a  $0.55/0.0002=2,750$ -fold range between  $k_{TH}$  and  $k_{U1}$ .

#### *Computational modeling reveals multiple functional abnormalities*

Accounting for the pattern of myocardial catecholaminergic abnormalities found in Lewy body diseases required multiple alterations in values for rate constants. For instance, as shown in Figure 3, an isolated decrease in the rate constant for VMAT acting on cytoplasmic dopamine ( $k_{VMAT\_DA}$ ) predicted increased cytoplasmic DOPAC (DOPACc) without a change in cytoplasmic DOPA (DOPAc), whereas Lewy body disease patients showed severely decreased rates of cardiac DOPA spillover (Table 1).

TH, LAAAD, and vesicular uptake of cytoplasmic dopamine occur in series (Figure 1). The calculated rate constants for these processes in the Lewy body disease group were 30%, 8%, and 74% of control. The series arrangement of these reactions (thick green arrows in Figure 1) predicted a 98.1% decrease in tissue dopamine content in the Lewy body disease group, which agrees with the empirical value of 96.9% ( $1-(0.0031/0.140)$  in Table 1).

The calculated rate constant for LAAAD in the Lewy body group was only 8% that in the controls. Based on post-mortem patterns of catechol concentrations, PD also involves markedly decreased LAAAD activity in the brain's nigrostriatal system (33, 34). LAAAD therefore seems a promising target for gene enhancement therapy (35).

NE synthesis in sympathetic nerves requires DBH, the intra-vesicular enzyme catalyzing the conversion of dopamine to NE. The calculated rate constant for DBH in the Lewy body disease group was not lower than in the controls. This finding indicates that the functional

abnormalities in cardiac sympathetic nerves in Lewy body diseases are not generalized to all aspects of catecholaminergic function. Similarly, the calculated rate constant for NE release was not decreased in the Lewy body group. The low empirical rate of cardiac NE spillover in Lewy body diseases (19% of control, Table 1) seems to reflect the depletion of releasable NE stores.

One may ask whether the obtained results would differ if, given the relatively high cytoplasmic concentration of tyrosine as substrate, TH were saturated under physiological conditions. The proportionate difference between the Lewy body and control groups in model-generated rate constants assuming first-order kinetics for TH was identical to the difference assuming enzyme saturation (zero-order kinetics). That is, after taking denervation into account, the same large decrease in TH activity was found in the Lewy body group regardless of enzyme saturation.

In the model the rate constant for vesicular leakage was set at 1.14% per minute in controls, based on previously published data (28); this value was increased in the Lewy body disease group because of previously published accelerated loss of myocardial  $^{18}\text{F}$ -dopamine-derived radioactivity (36). Increased sympathoneural NE turnover could be from decreased vesicular uptake or from increased vesicular leakage (2), and the model cannot separate these possibilities. For instance, the decrease in vesicular storage of dopamine in the Lewy body group could have reflected a 25.4% drop in the rate constant for vesicular uptake and 208% increase in the rate constant for leakage (as in Figure 1) but could also have reflected a  $25.4\% \times 208\% = 53.2\%$  drop in vesicular uptake and no change in the rate constant for vesicular leakage. Experiments on vesicles isolated from striatal tissue from patients with PD have noted markedly decreased vesicular uptake, with evidence for both decreased numbers of VMAT molecules and abnormal transport function of the protein itself (37).

The predominant mechanism of inactivation of released NE is reuptake (Uptake-1) mediated by the NET. Uptake-1 activity has been reported to be decreased in Lewy body diseases (25, 38); however, previous studies have not examined NET activity after taking denervation into account. The present kinetic model yielded a value for the Uptake-1 rate

constant ( $kU1$ ) in residual sympathetic neurons in Lewy body diseases that was only about 2% of control.

*Empirical testing of model predictions*

Predictions from the model were assessed by myocardial levels of catechols and catechol ratios in new cohorts of PD patients and controls. A vesicular storage defect (whether from decreased vesicular uptake or increased vesicular leakage) would be expected to increase tissue ratios of DHPG/NE, DOPAC/NE, and DOPAC/dopamine; these ratios in the PD group averaged 9.8, 11.2, and 14.8 times the corresponding values in the controls. Decreased LAAAD activity would increase ratios of DOPA/DOPAC, Cys-DOPA/DOPAC, and (DOPA+Cys-DOPA)/DOPAC, and in the PD group these averaged 5.1, 3.5, and 5.0 times control. TH activity in the residual sympathetic nerves in the PD group was estimated to be decreased by about 70% after taking denervation into account. An indirect estimate of Uptake-1 activity, the myocardial epinephrine concentration, was decreased to 14% of control; however, this could reflect denervation, NET dysfunction, or a combination of these abnormalities. In general, the new empirical data fit with the concept of attenuated catecholamine biosynthesis, vesicular storage, and NE recycling in residual myocardial sympathetic nerves in Lewy body diseases.

*A common cause?*

Is it possible that there is a single common cause for the pattern of functional abnormalities described here? Oxidative stress or decreased mitochondrial energy generation would seem likely culprits (39, 40). For LAAAD to catalyze dopamine synthesis from DOPA, however, requires neither oxygen nor energy, yet the calculated rate constant for LAAAD was substantially decreased in the Lewy body disease group. More generally, widespread oxidative stress or deficient mitochondrial energy generation would not account easily for the syndromic nature of Lewy body diseases, nor the relatively selective, profound catecholamine deficiencies found in the putamen and heart compared to other regions receiving catecholaminergic innervation.

A specific unifying mechanism may be harmful interactions between the catecholaldehyde 3,4-dihydroxyphenylacetaldehyde (DOPAL) and the protein alpha-synuclein (AS). DOPAL is an obligate intermediate in neuronal DA metabolism (Figure 1). DOPAL inhibits activities of both TH (21) and LAAAD (41). DOPAL also potently oligomerizes AS (41), converting the protein to oligomeric forms that impede vesicular functions (19), and AS also inhibits LAAAD (22). Moreover, DOPAL forms quinone-protein adducts with other proteins involved in catecholaminergic functions, including TH, LAAAD, and VMAT2, probably via spontaneous oxidation to DOPAL-quinone (41). Lewy body diseases all feature AS deposition in sympathetic noradrenergic nerves (42), and putamen DOPAL is built up in PD (43). Nevertheless, accumulation of neither DOPAL nor AS in catecholaminergic neurons has been shown to be pathogenic, as opposed to both being non-pathogenic biomarkers of the disease process.

### *Implications*

The present findings based on application of a novel computational modeling approach indicate that, rather than there being a single pathogenetic mechanism underlying cardiac NE deficiency—neuronal loss—there are multiple functional abnormalities in extant neurons in Lewy body diseases. Both decreased innervation and neuronal dysfunctions in residual neurons that are “sick but not dead” seem to contribute to the dramatic NE depletion found in the heart in PD and other Lewy body diseases.

It is reasonable to propose that an analogous phenomenon applies in central catecholaminergic neurons. Thus, there is evidence for denervation-independent abnormalities in vesicular storage, LAAAD activity, and aldehyde dehydrogenase activity in putamen tissue from patient with parkinsonian synucleinopathies (33, 36, 43).

Although the kinetic model presumed a balance of rates of gain and loss for each of the reactants, this equilibrium does not imply stability. On the contrary, the kinetic model does not involve negative feedback regulation—i.e., no homeostasis. Any perturbation would be unopposed. A systems approach involving compensatory negative feedback and progressively

declining homeostatic capacity seems required to model accurately the period of preclinical or prodromal disease.

The finding that a proportion of catecholaminergic neurons are “sick but not dead” offers hope that a disease-modification strategy might slow or prevent the progression of catecholaminergic neurodegeneration in this family of disorders. Understanding about how catecholaminergic neurons are dysfunctional may incite rational, mechanism-directed treatment. The “sick but not dead” concept also supports the possibility that one can develop pathophysiological biomarkers to detect the disease process in an early phase.

## **METHODS**

### **Subjects**

Data from previous publications were based on (a) trans-cardiac kinetic studies of tracer-labelled catecholamines during cardiac catheterization in 45 control subjects and 13 patients with Lewy body diseases (7 PAF, 6 PD with orthostatic hypotension,  $64 \pm 4$  years, 9 men) (28, 38); and (b) post-mortem studies of apical myocardial catechols in 23 control subjects and 8 patients with neurogenic orthostatic hypotension in the setting of a Lewy body disease (5 PD, 3 PAF) (2, 3). Data about rates of reactions in controls were obtained from a previously published study by Eisenhofer et al. in 1996 (28), except for a minor adjustment in the calculated rate of NE production in order to obey conservation of mass. Rates of reactions in Lewy body disease patients were from publications about the rate of appearance of endogenous NE in coronary sinus plasma (spillover) and arterial-coronary sinus differences in plasma concentrations of 3,4-dihydroxyphenylglycol (DHPG, the main neuronal metabolite of NE), 3,4-dihydroxyphenylacetic acid (DOPAC, the main neuronal metabolite of dopamine), and 3,4-dihydroxyphenylalanine (DOPA, the precursor of the catecholamines) (3, 38). Data about myocardial tissue amounts of catechols in the control and patient groups were obtained from publications about concentrations of these catechols as well as 5-S-cysteinyldopamine, a product of spontaneous oxidation of cytoplasmic dopamine) (2).

For all the subjects, written informed consent was obtained prior to participation in protocols approved by the Institutional Review Board of the National Institute of Neurological Disorders and Stroke, or else the next of kin gave written informed consent for post-mortem tissue harvesting for research purposes.

### **Kinetic Model**

A multi-compartment model was constructed depicting a total of 17 reactions involving 9 reactants in cardiac sympathetic nerves (Figure 1, Appendices 1 and 2). Table 2 lists reaction rates and amounts in the control and Lewy body nOH groups.

### **Testing Model Predictions**

To test predictions from the pattern of rate constants obtained by applying the kinetic model to previously published data, we used new empirical data about myocardial catechols and catechol ratios in cohorts of PD patients (N=11) and controls (N=11) of similar age. Coded samples of myocardial tissue from PD patients and control subjects were received from the Banner Sun Health Research Institute (Sun City, AZ) under a Material Transfer Agreement and assayed for catechol contents (2). The investigators and assay personnel were blinded as to the post-mortem neuropathologic diagnosis.

We reported previously on myocardial concentrations ratios of DHPG/NE, DOPAC/NE, and DOPAC/DA and their relationships to vesicular sequestration of cytoplasmic catecholamines in PD (2). Loss of sympathetic noradrenergic innervation alone would not be expected to alter these ratios. If there were a vesicular storage defect in residual myocardial sympathetic nerves, with a shift from vesicular sequestration to oxidative deamination of cytoplasmic catecholamines, then values for these ratios would be increased (Figure 1). If there were decreased LAAAD activity in residual cardiac sympathetic nerves, DOPA and 5-S-cysteinyldOPA (Cys-DOPA), which are proximal to the LAAAD step, would be built up with respect to DOPAC. If TH activity were decreased in residual sympathetic neurons, myocardial endogenous DOPA and Cys-DOPA levels would be decreased; however, since decreased LAAAD activity would increase levels of both compounds, to assess TH activity it was necessary to DOPA and Cys-DOPA levels for the decrease in LAAAD activity. Myocardial epinephrine content is derived substantially from neuronal uptake of epinephrine from the coronary arterial blood (44). If there were decreased NET activity in residual cardiac sympathetic neurons in Lewy body diseases, myocardial epinephrine content would therefore be decreased.

### **Statistics**

Mean values were expressed  $\pm$  1 standard error of the mean. A p value less than 0.05 defined statistical significance. Mean values for catechol contents and catechol ratios in the Lewy body disease patients and controls were compared by independent-means t-tests conducted on log-transformed data.

## **AUTHORS CONTRIBUTIONS**

David S. Goldstein: literature search, figures, study design, data collection, data analysis, data interpretation, writing

Mark Pekker: literature search, study design, data analysis, data interpretation, writing

Graeme Eisenhofer: literature search, data interpretation, writing

Yehonatan Sharabi: literature search, study design, data analysis, data interpretation, writing

## **CONFLICTS OF INTEREST:**

The Authors have no conflicts of interest to disclose.

## **ACKNOWLEDGEMENT AND FUNDING SOURCE:**

The research reported here was supported by the Division of Intramural Research, National Institute of Neurological Disorders and Stroke.

**REFERENCES**

1. Ehringer H, and Hornykiewicz O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system.]. *Wien Klin Wochenschr.* 1960;38:1236–9.
2. Goldstein DS, Sullivan P, Holmes C, Miller GW, Sharabi Y, and Kopin IJ. A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson disease. *J Neurochem.* 2014;131:219-28.
3. Goldstein DS, and Sharabi Y. The heart of PD: Lewy body diseases as neurocardiologic disorders. *Brain Res.* 2019;1702:74-84.
4. Kim JS, Shim YS, Song IU, Yoo JY, Kim HT, Kim YI, et al. Cardiac sympathetic denervation and its association with cognitive deficits in Parkinson's disease. *Parkinsonism Relat Disord.* 2009;15(9):706-8.
5. Nakamura T, Hirayama M, Yamashita F, Uchida K, Hama T, Watanabe H, et al. Lowered cardiac sympathetic nerve performance in response to exercise in Parkinson's disease. *Mov Disord.* 2010;25(9):1183-9.
6. Goldstein DS, Holmes C, Benth O, Sato T, Moak J, Sharabi Y, et al. Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. *Parkinsonism Relat Disord.* 2008;14(8):600-7.
7. Kim JS, Park HE, Oh YS, Lee SH, Park JW, Son BC, et al. Orthostatic hypotension and cardiac sympathetic denervation in Parkinson disease patients with REM sleep behavioral disorder. *J Neurol Sci.* 2016;362:59-63.
8. Oka H, Yoshioka M, Onouchi K, Morita M, Mochio S, Suzuki M, et al. Impaired cardiovascular autonomic function in Parkinson's disease with visual hallucinations. *Mov Disord.* 2007;22(10):1510-4.
9. Romagnolo A, Zibetti M, Merola A, Canova D, Sarchioto M, Montanaro E, et al. Cardiovascular autonomic neuropathy and falls in Parkinson disease: a prospective cohort study. *J Neurol.* 2019;266(1):85-91.

10. Nakamura T, Hirayama M, Hara T, Hama T, Watanabe H, and Sobue G. Does cardiovascular autonomic dysfunction contribute to fatigue in Parkinson's disease? *Mov Disord.* 2011;26(10):1869-74.
11. Goldstein DS, Holmes C, Sharabi Y, and Wu T. Survival in synucleinopathies: A prospective cohort study. *Neurology.* 2015;85(18):1554-61.
12. Amino T, Orimo S, Takahashi A, Uchihara T, and Mizusawa H. Profound cardiac sympathetic denervation occurs in Parkinson disease. *Brain Path.* 2005;15:29-34.
13. Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. *Acta Neuropathol.* 2008;115(4):437-44.
14. Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. *Brain.* 2008;131(Pt 3):642-50.
15. Fujishiro H, Frigerio R, Burnett M, Klos KJ, Josephs KA, Delledonne A, et al. Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. *Mov Disord.* 2008;23(8):1085-92.
16. Ghebremedhin E, Del Tredici K, Langston JW, and Braak H. Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson's disease: an anatomical study. *Acta Neuropathol.* 2009;118(6):777-84.
17. Takahashi M, Ikemura M, Oka T, Uchihara T, Wakabayashi K, Kakita A, et al. Quantitative correlation between cardiac MIBG uptake and remaining axons in the cardiac sympathetic nerve in Lewy body disease. *Journal of neurology, neurosurgery, and psychiatry.* 2015;86(9):939-44.
18. Goldstein DS, Holmes C, Kopin IJ, and Sharabi Y. Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases. *J Clin Invest.* 2011;121(8):3320-30.
19. Plotegher N, Berti G, Ferrari E, Tessari I, Zanetti M, Lunelli L, et al. DOPAL derived

- alpha-synuclein oligomers impair synaptic vesicles physiological function. *Sci Rep*. 2017;7:40699.
20. Volpicelli-Daley LA. Effects of alpha-synuclein on axonal transport. *Neurobiol Dis*. 2017;105:321-7.
  21. Mexas LM, Florang VR, and Doorn JA. Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite. *Neurotoxicology*. 2011;32(4):471-7.
  22. Tehranian R, Montoya SE, Van Laar AD, Hastings TG, and Perez RG. Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells. *J Neurochem*. 2006;99(4):1188-96.
  23. Nagatsu T, and Sawada M. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. *J Neural Transm Suppl*. 2007(72):113-20.
  24. Meredith IT, Eisenhofer G, Lambert GW, Dewar EM, Jennings GL, and Esler MD. Cardiac sympathetic nervous activity in congestive heart failure. Evidence for increased neuronal norepinephrine release and preserved neuronal uptake. *Circulation*. 1993;88(1):136-45.
  25. Polinsky RJ, Goldstein DS, Brown RT, Keiser HR, and Kopin IJ. Decreased sympathetic neuronal uptake in idiopathic orthostatic hypotension. *Ann Neurol*. 1985;18:48-53.
  26. Sasidharakurup H, Melethadathil N, Nair B, and Diwakar S. A Systems Model of Parkinson's Disease Using Biochemical Systems Theory. *OMICS*. 2017;21(8):454-64.
  27. Eisenhofer G, Brush JE, Cannon RO, III, Stull R, Kopin IJ, and Goldstein DS. Plasma dihydroxyphenylalanine and total body and regional noradrenergic activity in humans. *J Clin Endocrinol Metab*. 1989;68:247-55.
  28. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, et al. Cardiac sympathetic nerve function in congestive heart failure. *Circulation*. 1996;93:1667-76.
  29. Nagatsu T, Levitt M, and Udenfriend S. Tyrosine Hydroxylase. The Initial Step in Norepinephrine Biosynthesis. *J Biol Chem*. 1964;239:2910-7.
  30. Eisenhofer G, Kopin IJ, and Goldstein DS. Catecholamine metabolism: a contemporary

- view with implications for physiology and medicine. *Pharmacol Rev.* 2004;56(3):331-49.
31. Goldstein DS, Katzper M, Linares OA, and Kopin IJ. Kinetic model for the fate of the sympathoneural imaging agent 6-[18F]fluorodopamine in the human heart: A novel means to assess cardiac sympathetic neuronal function. *Naunyn-Schmiedeberg's Arch Pharmacol.* 2002;365:38-49.
  32. Gilinsky MA, Faibushevish AA, and Lunte CE. Determination of myocardial norepinephrine in freely moving rats using in vivo microdialysis sampling and liquid chromatography with dual-electrode amperometric detection. *J Pharm Biomed Anal.* 2001;24(5-6):929-35.
  33. Goldstein DS, Sullivan P, Holmes C, Mash DC, Kopin IJ, and Sharabi Y. Determinants of denervation-independent depletion of putamen dopamine in Parkinson's disease and multiple system atrophy. *Parkinsonism Relat Disord.* 2017;35:88-91.
  34. Ciesielska A, Samaranch L, San Sebastian W, Dickson DW, Goldman S, Forsayeth J, et al. Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial. *PLoS One.* 2017;12(2):e0169965.
  35. Mittermeyer G, Christine CW, Rosenbluth KH, Baker SL, Starr P, Larson P, et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. *Hum Gene Ther.* 2012;23(4):377-81.
  36. Goldstein DS, Holmes C, Sullivan P, Mash DC, Sidransky E, Stefani A, et al. Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration. *Parkinsonism Relat Disord.* 2015;21(9):1013-22.
  37. Pifl C, Rajput A, Reither H, Blesa J, Cavada C, Obeso JA, et al. Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum. *J Neurosci.* 2014;34(24):8210-8.
  38. Goldstein DS, Holmes C, Li ST, Bruce S, Metman LV, and Cannon RO, 3rd. Cardiac sympathetic denervation in Parkinson disease. *Ann Intern Med.* 2000;133(5):338-47.


39. Perfeito R, Cunha-Oliveira T, and Rego AC. Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse. *Free Radic Biol Med.* 2013;62:186-201.
40. Schapira AH, and Jenner P. Etiology and pathogenesis of Parkinson's disease. *Mov Disord.* 2011;26(6):1049-55.
41. Jinsmaa Y, Sharabi Y, Sullivan P, Isonaka R, and Goldstein DS. 3,4-Dihydroxyphenylacetaldehyde-induced protein modifications and their mitigation by N-acetylcysteine. *J Pharmacol Exp Ther.* 2018;366(1):113-24.
42. Isonaka R, Sullivan P, Jinsmaa Y, Corrales A, and Goldstein DS. Spectrum of abnormalities of sympathetic tyrosine hydroxylase and alpha-synuclein in chronic autonomic failure. *Clin Auton Res.* 2018;28(2):223-30.
43. Goldstein DS, Sullivan P, Holmes C, Miller GW, Alter S, Strong R, et al. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. *J Neurochem.* 2013;126(5):591-603.
44. Eisenhofer G, Smolich JJ, and Esler MD. Disposition of endogenous adrenaline compared to noradrenaline released by cardiac sympathetic nerves in the anaesthetized dog. *Naunyn Schmiedebergs Arch Pharmacol.* 1992;345(2):160-71.
45. Melamed E, Glaeser B, Growdon JH, and Wurtman RJ. Plasma tyrosine in normal humans: effects of oral tyrosine and protein-containing meals. *J Neural Transm.* 1980;47(4):299-306.
46. Goldstein DS, Cannon RO, Quyyumi A, Chang P, Duncan M, Brush JE, Jr., et al. Regional extraction of circulating norepinephrine, DOPA, and dihydroxyphenylglycol in humans. *J Auton Nerv Sys.* 1991;34:17-35.
47. Goldstein DS, Brush JE, Jr., Eisenhofer G, Stull R, and Esler M. In vivo measurement of neuronal uptake of norepinephrine in the human heart. *Circulation.* 1988;78:41-8.
48. Bindel D, Friedman M, Govaerts W, Hughes J, and Kuznetsov YA. Numerical computation of bifurcations in large equilibrium systems in MATLAB. *J Comput Appl Math.*

2014;261:232-48.

49. Cheng FC, Kuo JS, Chia LG, and Dryhurst G. Elevated 5-S-cysteinyl dopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease. *J Neural Transm.* 1996;103(4):433-46.
50. Goldstein DS, Jinsmaa Y, Sullivan P, and Sharabi Y. N-Acetylcysteine prevents the increase in spontaneous oxidation of dopamine during monoamine oxidase inhibition in PC12 cells. *Neurochem Res.* 2017;42(11):3289-95.
51. Ferris RM, and Tang FL. Comparison of the effects of the isomers of amphetamine, methylphenidate and deoxypipradrol on the uptake of 1-[3H]norepinephrine and [3H]dopamine by synaptic vesicles from rat whole brain, striatum and hypothalamus. *J Pharmacol Exp Ther.* 1979;210(3):422-8.


## FIGURES AND FIGURE LEGENDS

Figure 1: Concept diagram depicting steps of catecholamine synthesis, storage, release, recycling, and metabolism in myocardial sympathetic nerves.




Reactions are in italics and amounts of reactants in plain text. Font sizes correspond roughly to amounts of reactants. Green arrows indicate dopamine (DA) synthesis and blue arrows norepinephrine (NE) vesicular uptake and leakage. After tyrosine (TYR) uptake, cytoplasmic TYR (TYR<sub>c</sub>) is converted to DOPA via tyrosine hydroxylase (TH). Cytoplasmic DOPA (DOPAc) is converted to DA via L-aromatic-amino-acid decarboxylase (LAAAD) or undergoes spontaneous oxidation to form 5-S-cysteinyldOPA (Cys-DOPA). Cytoplasmic DA (DA<sub>c</sub>) is converted to 3,4-dihydroxyphenylacetaldehyde (DOPAL) via monoamine oxidase (MAO), undergoes spontaneous oxidation to form 5-S-cysteinylda (Cys-DA), or is taken up into vesicular via the vesicular monoamine transporter (VMAT). DOPAL is metabolized by aldehyde dehydrogenase (ALDH) to form 3,4-dihydroxyphenylacetic acid (DOPAC) or by aldehyde/aldose reductase (AR) to form 3,4-dihydroxyphenylethanol (DOPET). DA in vesicles is converted to norepinephrine (NE) via dopamine-beta-hydroxylase (DBH) or leaks passively into the cytoplasm. NE in vesicles is released into the extracellular fluid or leaks passively into the cytoplasm. Cytoplasmic NE (NE<sub>c</sub>) is converted to 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) via MAO, and DOPEGAL is metabolized to 3,4-dihydroxyphenylglycol (DHPG) via AR. NE in the extracellular fluid (NE<sub>e</sub>) is taken up into the nerve by Uptake-1 (U1), spills over into the cardiac venous drainage (NESO), or is removed by extraneuronal uptake (Uptake-2, U2). Circulating epinephrine (EPI) can be taken up into the nerve by U1 and transported into vesicles via the VMAT.

Figure 2: Calculated rate constants for processes related to catecholamine synthesis and fate in cardiac sympathetic nerves.




Pink is the intraneuronal cytoplasm; blue and green are vesicles; and white is extracellular fluid (ECF). Numbers in gray are values in control subjects and in red values in patients with a Lewy body disease. Green arrows highlight steps in dopamine (DA) synthesis; blue arrows highlight steps in vesicular norepinephrine (NE<sub>v</sub>) turnover. See text for other abbreviations.

Figure 3: Model-generated curves relating amounts of intra-neuronal reactants to fractional changes of rate constants.




(A) Cytoplasmic DOPA (DOPAc) and DOPAC (DOPACc) vs. kVMAT\_DA; (B) Cytoplasmic DOPA (DOPAc) and DOPAC (DOPACc) vs. kLAAAD; (C) Vesicular NE (NEv) and DA (DAv) vs. kU1; (D) Cytoplasmic DOPA (DOPAc) and DOPAC (DOPACc) vs. kTH. Vertical dashed lines indicate rate constants in Lewy body disease patients as a fraction of corresponding rate constants in controls. No single change in kVMAT\_DA, kLAAAD, kU1, or kTH predicts the actual pattern of alterations in reactant amounts in the Lewy body compared to the control group.

Figure 4: Box and whisker plots for post-mortem myocardial concentrations of catechols in controls (gray) and Parkinson disease (PD) patients (red).



Highest, 3<sup>rd</sup> quartile, median, 2<sup>d</sup> quartile, and lowest values are shown. Numbers of subjects are in rectangles. Numbers in italics are p values for independent-means t-tests conducted on log-transformed data comparing the control and PD groups. Abbreviations: NE=norepinephrine; DA=dopamine; DHPG=3,4-dihydroxyphenylglycol; DOPA=3,4-dihydroxyphenylalanine. NE, DA, and DHPG levels in PD are drastically decreased compared to controls, without a significant group difference in DOPA.

Figure 5: Box and whisker plots for post-mortem indices of sympathetic intra-neuronal functions in controls (gray) and Parkinson disease (PD) patients (red).



Highest, 3<sup>rd</sup> quartile, median, 2<sup>d</sup> quartile, and lowest values are shown. Numbers of subjects are in rectangles. Numbers in italics are p values for independent-means t-tests conducted on log-transformed data comparing the control and PD groups. Abbreviations: LAAAD=L-aromatic-amino-acid decarboxylase; DA=dopamine; DHPG=3,4-dihydroxyphenylglycol; DOPA=3,4-dihydroxyphenylalanine; DOPAC=3,4-dihydroxyphenylacetic acid; Inv.=inverse; NE=norepinephrine; TH=tyrosine hydroxylase; VMAT2=type 2 vesicular monoamine transporter. DHPG/NE and DOPAC/NE ratios provided inverse indices of VMAT2 activity. The sum of 5-S-cysteinylDOPA+DOPA, divided by the sum of DA and its metabolites DOPAC and 3,4-dihydroxyphenylethanol, provided an inverse index of LAAAD activity. The sum of 5-S-cysteinylDOPA+DOPA, adjusted for LAAAD activity, provided an index of TH activity. The results indicate decreased VMAT2, LAAAD, and TH activities in PD compared to controls.

**Table 1: Spillover (SO) rates and myocardial catechol concentrations (mean values  $\pm$  SEM) in control subjects and patients with Lewy body diseases.** Numbers in parentheses are numbers of subjects.

<b>Rate</b>	<b>Control</b>	<b>Lewy</b>	<b>p Lewy v Control</b>
<i>pmol/min</i>			
Myo. DHPG SO	733 $\pm$ 51 (45)	38 $\pm$ 25 (13)	<0.00001
Myo. NE SO	99 $\pm$ 9 (45)	19 $\pm$ 4 (13)	0.00001
Myo. DOPA SO	219 $\pm$ 28 (45)	35 $\pm$ 7 (11)	0.00210
Myo. DOPAC SO	180 $\pm$ 34 (38)	4 $\pm$ 15 (11)	0.00773
<b>Concentration</b>	<b>Control</b>	<b>Lewy</b>	<b>p Lewy v Control</b>
<i>pmol/mg wet weight</i>			
Myo. NE	2.11 $\pm$ 0.24 (26)	0.045 $\pm$ 0.013 (28)	<0.00001
Myo. DA	0.140 $\pm$ 0.034 (26)	0.0031 $\pm$ 0.0006 (22)	<0.00001
Myo. DHPG	0.111 $\pm$ 0.035 (26)	0.025 $\pm$ 0.017 (21)	<0.00001
Myo. DOPAC	0.046 $\pm$ 0.010 (25)	0.010 $\pm$ 0.003 (26)	0.00021
Myo. DOPA	0.26 $\pm$ 0.06 (26)	0.21 $\pm$ 0.03 (28)	ns.

-----

**Note:** Individual data and descriptive statistics are in Supplementary Spreadsheets A and B.

**Table 2: Reactant amounts and reaction rates under equilibrium conditions in control**

**subjects.** All reactant amounts are in nmoles. All rates are in nmoles/min. Ranges based on 25% and 75% quartiles of the empirical median values.

**Amounts**

<b>REACTANT</b>	<b>PARAMETER</b>	<b>VALUE</b>	<b>RANGE</b>
1 TYRc	TYRc Amount	8747	
2 DOPAc	DOPAc Amount	142	105-200
3 DAc	DAc Amount	0.6	
4 DOPACc	DOPACc Amount	25	10-75
5 DAv	DAv Amount	76	30-110
6 NEv	NEv Amount	1150	885-1771
7 NEe	NEe Amount	0.14	
8 NEc	NEc Amount	2.1	
9 DHPGc	DHPGc Amount	60	47-165

**Rates**

<b>REACTION</b>	<b>PARAMETER</b>	<b>VALUE</b>	<b>RANGE</b>
1 TYR_Uptake	TYR Uptake Rate to TYRc	56	34-89
2 TYR_Loss	TYRc Loss Rate to ECF	54	33-87
3 TH	TYRc Conversion Rate to DOPAc	1.8	1.1-2.8
4 LAAAD	DOPAc Conversion Rate to DAc	1.5	1.2-1.8
5 DOPAc_Loss	DOPAc Exit Rate from the Model	0.22	0.15-0.33
6 VMAT_DA	DAc Vesicular Uptake Rate	2.2	1.8-2.7
7 Leak_DA	DAv Loss Rate to Cytoplasm	0.87	0.66-1.08
8 DBH	DAv Conversion Rate to NEv	1.4	1.4-3.6
9 MAO_DA	DAc Conversion Rate to DOPACc	0.18	0.11-0.29
10 DOPACc_Loss	DOPACc Exit Rate from the Model	0.18	0.11-0.29
11 VMAT_NE	Vesicular Uptake Rate of NEc	14	11-22

12	Leak_NE	NEv Loss Rate to Cytoplasm	13	10-20
13	NE_Release	NEv Release Rate to ECF	2.6	1.4-3.7
14	U1	NEe Reuptake Rate to NEc	2.4	1.3-3.5
15	MAO_NE	NEc Conversion Rate to DHPGc	1.2	0.8-1.8
16	DHPGc_Loss	DHPGc Exit Rate from the Model	1.2	0.8-1.8
17	NEe_Loss	NEe Exit Rate from the Model	0.21	0.11-0.29

**Table 3: Reactant amounts and reaction rates under equilibrium conditions in Lewy body disease patients.** All reactant amounts are in nmoles. All rates are in nmoles/min. Ranges based on 25% and 75% quartiles of the empirical median values.

<b>REACTANT</b>	<b>PARAMETER</b>	<b>VALUE</b>	<b>RANGE</b>
1 TYRc	TYRc Amount	2239	
2 DOPAc	DOPAc Amount	114	61-182
3 DAc	DAc Amount	0.05	
4 DOPACc	DOPACc Amount	5.5	4.3-11.0
5 DAv	DAv Amount	1.7	1.3-2.6
6 NEv	NEv Amount	25	12-65
7 NEe	NEe Amount	0.14	
8 NEc	NEc Amount	0.3	
9 DHPGc	DHPGc Amount	14	4-40
<b>REACTION</b>	<b>PARAMETER</b>	<b>VALUE</b>	<b>RANGE</b>
1 TYR_Uptake	TYR Uptake Rate to TYRc	14.2	0-43
2 TYR_Loss	TYRc Loss Rate to ECF	14.1	0-43
3 TH	TYRc Conversion Rate to DOPAc	0.14	0-0.42
4 LAAAD	DOPAc Conversion Rate to DAc	0.10	0-0.31
5 DOPAc_Loss	DOPAc exit Rate from the Model	0.035	0.014-0.040
6 VMAT_DA	DAc Vesicular Uptake Rate	0.14	0-0.42
7 Leak_DA	DAv Loss Rate to Cytoplasm	0.04	0-0.12
8 DBH	DAv Conversion Rate to NEv	0.10	0.05-0.26
9 MAO_DA	DAc Conversion Rate to DOPACc	0.004	0-0.012
10 DOPACc_Loss	DOPACc Exit Rate from the Model	0.004	0-0.012
11 VMAT_NE	Vesicular Uptake Rate of NEc	0.56	0.27-1.47
12 Leak_NE	NEv Loss Rate to Cytoplasm	0.57	0.28-1.51
13 NE_Release	NEv Release Rate to ECF	0.08	0.03-0.11

14	U1	NEe Reuptake Rate to NEc	0.04	0.02-0.06
15	MAO_NE	NEc Conversion Rate to DHPGc	0.06	0.01-0.10
16	DHPGc_Loss	DHPGc Exit Rate from the Model	0.06	0.01-0.10
17	NEe_Loss	NEe Exit Rate from the Model	0.04	0.01-0.05

**Table 4: Calculated rate constants (in units of  $\text{min}^{-1}$ ) for the model of the cardiac sympathetic nervous system in healthy humans and patients with Lewy body disease.** All processes are presumed to be unidirectional first-order processes, except for the neuronal uptake of tyrosine, which is presumed to occur at a constant rate. Tabulated values are for equilibrium conditions. There are 17 rate constants for reactions among 9 reactants.

<b>Rate Constant</b>	<b>Process</b>	<b>Control</b>	<b>Lewy</b>
1. kTYR_Uptake	---> TYR (cyto.)	56	14
2. kTYR_Loss	TYR (cyto.) --->	0.0062	0.0063
3. kTH	TYR (cyto.) ---> DOPA (cyto.)	0.00020	0.000062
4. kLAAAD	DOPA (cyto.) ---> DA (cyto.)	0.011	0.00091
5. kDOPA_Loss	DOPA (cyto.) --->	0.0016	0.00031
6. kMAO_DA	DA (cyto.) ---> DOPAC (cyto.)	0.30	1.10
7. kVMAT_DA	DA (cyto.) ---> DA (vesicles)	3.75	2.79
8. kDBH	DA (vesicles) ---> NE (vesicles)	0.018	0.058
9. kLeak_DA	DA (vesicles) ---> DA (cyto.)	0.011	0.024
10. kNE_Release	NE (vesicles) ---> NE (ECF)	0.0023	0.0032
11. kLeak_NE	NE (vesicles) ---> NE (cyto.)	0.011	0.023
12. kVMAT_NE	NE (cyto.) ---> NE (vesicles)	6.72	1.85
13. kMAO_NE	NE (cyto.)---> DHPG (cyto.)	0.56	0.20
14. kU1	NE (ECF) ---> NE (cyto.)	17.1	0.29
15. kDOPAC_Loss	DOPAC (cyto.) --->	0.0072	0.00073
16. kDHPG_Loss	DHPG (cyto.) --->	0.020	0.0043
17. kNE_Loss	NE (ECF) --->	1.49	0.28

----

Abbreviations: cyto.=cytoplasm; ECF=extracellular fluid; DA=dopamine; DOPAC=3,4-dihydroxyphenylacetic acid; DBH=dopamine-beta-hydroxylase; DHPG=3,4-dihydroxyphenylglycol; LAAAD=L-aromatic-amino-acid decarboxylase; Leak=leak from

vesicles into cytoplasm; MAO=monoamine oxidase; NE=norepinephrine; TH=tyrosine hydroxylase; TYR=tyrosine; U1=neuronal uptake (Uptake-1) via the cell membrane norepinephrine transporter); VMAT=vesicular monoamine transporter.